Three- and seven-month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone-sensitive prostate cancer: Results from SWOG S1216, a phase 3 randomized trial of androgen deprivation plus orteronel or bicalutamide

Authors

Mamta Parikh, University of California, Davis
Russell K Pachynski, Washington University School of Medicine in St. Louis
et al.

Journal

European Urology Oncology

Publication Date

10-1-2024

Volume

7

Issue

5

First Page

1097

Last Page

1104

Document Type

Open Access Publication

DOI

10.1016/j.euo.2024.03.001

Rights and Permissions

Parikh M, Tangen C, Hussain MHA, Gupta S, Callis S, Jo Y, Harzstark A, Paller CJ, George S, Zibelman MR, Cheng HH, Maughan BL, Zhang J, Pachynski RK, Bryce AH, Lin DW, Quinn DI, Lerner SP, Thompson IM, Dorff TB, Lara PN, Agarwal N. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. 2024 Oct;7(5):1097-1104. doi: 10.1016/j.euo.2024.03.001. Copyright 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Recommended Citation

Parikh, Mamta; Pachynski, Russell K; and et al., "Three- and seven-month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone-sensitive prostate cancer: Results from SWOG S1216, a phase 3 randomized trial of androgen deprivation plus orteronel or bicalutamide." European Urology Oncology. 7, 5. 1097 - 1104. (2024).
https://digitalcommons.wustl.edu/oa_4/4556

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.